ClinicalTrials.gg
Not yet recruitingNCT07858006Updated Oct 7, 2026

Brain-computer Interface (BCI)-Guided Upper Limb Neurorehabilitation for Acute Stroke With the recoveriX System

An interventional study of BCI-Based Neurorehabilitation with Functional Electrical Stimulation (recoveriX) in Stroke, sponsored by Tan Tock Seng Hospital. Not yet recruiting. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Tan Tock Seng Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stroke by Tan Tock Seng Hospital — 3 open to participants now, 6 under way, none of them phase 3. Stroke · Tan Tock Seng Hospital.

Planned enrollment
13th of 20
12 · median 17
Started
2026
the only one that year
No phase
19 of 29
2 open now
Registered
29th of 29
by date

Among the 29 studies in Stroke by Tan Tock Seng Hospital, this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 19 with no phase, and was the 29th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 29 studies in Stroke by Tan Tock Seng Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stroke by Tan Tock Seng Hospital, or all of them as a file.
02

Study summary

Stroke is a leading cause of neurological disability and upper limb impairment. While conventional rehabilitation options exist, brain-computer interface (BCI)-based neurorehabilitation has emerged as a promising approach that records and decodes neural signals to drive rehabilitation devices or functional electrical stimulation. By re-coupling cortical motor intent to limb movement, BCI systems restore closed-loop neurofeedback and facilitate neuroplasticity through residual neural pathways. Motor intent is detected non-invasively via scalp electroencephalography (EEG), using characteristic changes in mu and beta rhythm activity known as event-related desynchronisation (ERD). This study aims to investigate how these electrophysiological signals change over time following stroke and their implications for BCI-based rehabilitation.

Read the detailed description

Stroke is a leading cause of neurological disability, resulting in significant upper limb impairment. Current rehabilitation approaches include conventional occupational therapy, constraint-induced movement therapy, and robot-assisted therapy. Brain-computer interface (BCI)-based neurorehabilitation has emerged as a promising addition, whereby neural signals are recorded, decoded to determine motor intent, and used to drive external devices or functional electrical stimulation of the patient's own muscles.

A key mechanism underlying BCI-based rehabilitation is the restoration of closed-loop neurofeedback. Conventional rehabilitation lacks a direct link between a patient's volitional intent and limb movement. BCI systems address this by re-coupling cortical motor signals to end-effector activity, bypassing lesioned neural pathways and facilitating Hebbian neuroplasticity. Sensory feedback from limb movement further reinforces this closed loop, promoting recovery of motor function through residual and alternative neural pathways.

Motor intent is measured non-invasively using scalp electroencephalography (EEG), which captures oscillatory brain activity - particularly the mu (8-13 Hz) and beta (13-30 Hz) rhythms - that correlate with motor preparation and execution. During movement intent, characteristic reductions in these rhythms, known as event-related desynchronisation (ERD), can be detected algorithmically and used to control rehabilitation devices. Following stroke, these electrophysiological signals are known to be altered, though how they evolve over time remains an open question that this study aims to address.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Brain Computer Interface
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between age 21 to 80 years with hemorrhagic or ischemic stroke
  • Stroke onset within 2-12 weeks
  • Any demonstrated voluntary finger flexion or finger extension Oxford Medical Research Council (MRC) grade 0 to 4 (total 5)
  • (MoCA) > 20
  • Ability to understand written and spoken instructions, as well as stable medical and neurological status.

Exclusion criteria

Exclusion Criteria:

  • Presence of previous diagnosis of stroke
  • Implanted pacemaker or continuous infusion pump
  • History of seizures or past history of epilepsy
  • Recent neurosurgery
  • Medical instability deemed by study team
  • Severe blindness
  • Anticipated \<6 months
  • Hemodialysis
  • Inability to obey 1-step commands
  • Severe aphasia, or dysarthria
  • Severe arm/hand pain (Visual Analog Scale >4/10) or severe hemi anesthesia or spasticity in the paretic arm (modified Ashworth scale MAS >2, total 4)
  • Fixed shoulder or finger joint contractures, active arthritis in any upper limb joint
  • Inability to tolerate upright supported sitting posture for at least 45 minutes
  • Disorders of consciousness or altered arousal states precluding active participation in the task.
  • Pregnant women will be excluded from the study as the safety of FES (electrical stimulations) on foetus is unclear.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    BCI-Based Neurorehabilitation with Functional Electrical Stimulation (recoveriX)

    Device: BCI-Based Neurorehabilitation with Functional Electrical Stimulation (recoveriX)

Interventions

  • DeviceBCI-Based Neurorehabilitation with Functional Electrical Stimulation (recoveriX)

    Participants will undergo BCI-based neurorehabilitation using the FDA-approved recoveriX system, comprising a wet-electrode EEG cap, EEG signal processing software, and a functional electrical stimulator (FES). Treatment consists of up to 12 sessions over 3 to 4 weeks (2-3 sessions/week), supervised by a trained study team member, alongside usual inpatient rehabilitation. Each session involves motor imagery (MI) of finger extension across 3 blocks of 80 trials (240 total). Each trial begins with a 2-second baseline, followed by an auditory and visual cue to imagine finger extension for 5 seconds. If MI is detected (assessed every 200 ms), FES is delivered to the finger extensors (50 Hz, 300 µs pulse width), titrated to produce movement without pain. Real-time feedback is provided, and a session report is generated for review. Within 2 hours of each session, participants undergo 45 minutes of conventional standard-of-care occupational therapy.

06

What researchers measure

Primary outcomes

  1. Functional Independence Measure (FIM)

    An 18-item clinical assessment tool used to measure a patient's level of disability and determine how much assistance they require to perform basic activities of daily living. Minimum score: 18 (Patient requires total assistance for all 18 tasks), maximum score: Maximum score: 126 (Patient is completely independent in all 18 tasks), with higher score indicating better function.

    Time frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)

  2. Fugl-Meyer Motor Assessment (FMA) scale

    Change in Fugl Meyer Motor Assessment score in the affected arm, minimum: 0, maximum: 66 with higher scores indicating greater levels of mobility function

    Time frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)

  3. Action Research Arm Test (ARAT) Score

    Functional and dexterity score in the affected arm evaluated using 19 tests of motor function across 4 subsets; minimum score = 0, maximum score = 57, with higher score indicating better function.

    Time frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)

  4. Stroke Impact Scale v3.0

    A patient-reported questionnaire used to evaluate how a stroke impacts health and quality of life. Patients rate how difficult tasks are on a 5-point Likert scale (1 = "could not do it at all" to 5 = "not difficult at all"). Scores for each domain are then standardized to range from 0 to 100, with higher scores indicating better functioning and a higher quality of life. An additional visual scale asks patients to estimate their overall stroke recovery from 0 (no recovery) to 100 (full recovery).

    Time frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)

  5. EQ-5D-5L

    EQ-5D-5L is a standardized, patient-reported questionnaire used globally to evaluate health-related quality of life. It measures 5 dimensions of health: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each area features 5 severity levels, from "no problems" to "extreme problems".

    Time frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 14 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedBarthel IndexTime frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)
Oct 7, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 7, 2026
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedBarthel IndexTime frame: Weeks 0 (baseline), 3-4 (end training), 12, and 24 (follow-up)
    + 2 other changes: identifiers and arm descriptions
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858006
Collaborators
National Neuroscience Institute
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Xin Yi Lim
Contact
xin.yi.lim1@nhghealth.com.sg
63596312
Yu Tung Lo
principal investigator · National Neuroscience Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion